Dermatological aspects of the use of Cyclosporin A for prophylaxis of graft-versus-host disease
- 1 April 1984
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 110 (4) , 469-474
- https://doi.org/10.1111/j.1365-2133.1984.tb04662.x
Abstract
Oral Cyclosporin A (CyA) was given for the prophylaxis of graft-versus-host disease (GVHD) to sixty-seven patients receiving a bone marrow transplant, and was found to be extremely effective in reducing the severity of acute GVHD. Side-effects of CyA included hypertrichosis, gum hypertrophy, and a rare but serious 'capillary leak' syndrome.Keywords
This publication has 9 references indexed in Scilit:
- Transplantation: The Problem of Limited ResourcesNew England Journal of Medicine, 1983
- Sezary syndrome: transformation to a high grade T-cell lymphoma after treatment with Cyclosporin AClinical and Experimental Dermatology, 1983
- Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients.BMJ, 1982
- HYPERTENSION AND CONVULSIONS IN CHILDREN RECEIVING CYCLOSPORIN AThe Lancet, 1982
- Cyclosporin A blocks receptors for HLA-DR antigens on T cellsNature, 1981
- Response of graft versus host disease to high doses of methyl prednisoloneClinical and Laboratory Haematology, 1981
- TWO CASES OF BENIGN LUMPS AFTER TREATMENT WITH CYCLOSPORIN AThe Lancet, 1980
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980
- CYCLOSPORIN A FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN MANThe Lancet, 1978